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Background: The major targets of HIV infection in humans are CD4+ T cells. CD4+ T cell depletion is a hallmark of
AIDS. Previously, the SCID-hu thy/liv model was used to study the effect of HIV on thymopoeisis in vivo. However,
these mice did not develop high levels of peripheral T cell reconstitution and required invasive surgery for infection
and analysis. Here, we describe a novel variant of this model in which thy/liv implantation results in systemic
reconstitution with human T cells in the absence of any other human hematopoietic lineages.
Results: NOD/SCID-hu thy/liv and NSG-hu thy/liv mice were created by implanting human fetal thymus and liver
tissues under the kidney capsule of either NOD/SCID or NSG mice. In contrast to NOD/SCID-hu thy/liv mice that
show little or no human cells in peripheral blood or tissues, substantial systemic human reconstitution occurs in
NSG-hu thy/liv. These mice are exclusively reconstituted with human T cells (i.e. T-cell only mice or TOM). Despite
substantial levels of human T cells no signs of graft-versus-host disease (GVHD) were noted in these mice over a
period of 14 months. TOM are readily infected after parenteral exposure to HIV-1. HIV replication is sustained in
peripheral blood at high levels and results in modest reduction of CD4+ T cells. HIV-1 replication in TOM responds
to daily administration of combination antiretroviral therapy (ART) resulting in strong suppression of virus
replication as determined by undetectable viral load in plasma. Latently HIV infected resting CD4+ T cells can be
isolated from suppressed mice that can be induced to express HIV ex-vivo upon activation demonstrating the
establishment of latency in vivo.
Conclusions: NSG-hu thy/liv mice are systemically reconstituted with human T cells. No other human lymphoid
lineages are present in these mice (i.e. monocytes/macrophages, B cells and DC are all absent). These T cell only
mice do not develop GVHD, are susceptible to HIV-1 infection and can efficiently maintain virus replication. HIV
infected TOM undergoing ART harbor latently infected, resting CD4+ T cells.Background
SCID-hu thy/liv mice develop a bona-fide human thymic
organ and have a marginal level of systemic recon-
stitution with human T cells [1,2]. The human thymic
organoid present in the SCID-hu model is susceptible to
HIV infection [3]. However, infection of these animals
requires this tissue to be surgically exposed and virus
administration via direct injection [4]. HIV injection
results in infection of the human thymocytes present but
there is no viremia in these mice, thus analysis of virus* Correspondence: victor_garcia@med.unc.edu
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reproduction in any medium, provided the orreplication and its effect on thymocytes requires surgical
removal of a piece of tissue [4]. Subsequent monitoring
of infection over time also requires additional surgical
collection of tissue for analysis. Although the use of this
model is extremely labor intensive and requires large
numbers of animals to make meaningful observations,
the SCID thy/liv model has been extensively used to
evaluate HIV pathogenesis of the thymus, the effect of
HIV on thymocyte development, the establishment of
HIV latency in thymocytes in vivo, the efficacy of anti-
viral drugs on thymocytes and the role of auxiliary genes
of HIV in virus replication and CD4+ thymocyte destruc-
tion [5-8].tral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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several other novel strains of mice have been derived
with a higher degree of immune suppression. These
include the NOD/SCID and the NOD/SCID common
gamma chain null (NSG) strains of immunodeficient
mice [1]. Both of these strains have been extensively and
successfully used in the derivation of a variety of human-
ized mouse models [9]. However, neither of these two
strains has been extensively used to produce humanized
thy/liv implanted mice [10].
Resting CD4+ T cells represent a well-characterized
reservoir for latent HIV-1 infection, and this reservoir
persists long-term despite treatment with highly active
antiretroviral therapy (HAART) [11-13]. Incubating
resting CD4+ T cells with CCL19, secreted by mature
dendritic cells, ex vivo increases HIV-1 integration effi-
ciency [14]. Additionally, the chemokines CXCL9 and
CXCL10, secreted by monocyte-derived cells and indu-
ced by IFN-γ production, seem to mediate similar
effects in resting T cells [11,14-16]. Secretion of IL-7
by dendritic cells may be important for the survival of
memory T cells, and secretion of IL-15 by macro-
phages and other mononuclear phagocytes is import-
ant for the low level of proliferation necessary to
maintain a resting memory pool over time [17]. Thus
while it is known that several myeloid-derived cell
types secrete cytokines and chemokines that facilitate
the development of latency and maintain the resting
CD4+ T cell pool, whether or not these cells are neces-
sary for the establishment of latency in vivo remains
unknown [18].
With the long-term goal of obtaining a better un-
derstanding of HIV replication, CD4+ T cell depletion,
HIV latency and persistence in vivo, we sought to
study HIV-1 in a humanized mouse model that pos-
sesses human T cells but is devoid of human myeloid
(and B) cells. To this effect, we implanted human
thymus and liver into NOD/SCID and NSG mice. In
this study we show that whereas NOD/SCID hu thy/
liv mice do not develop high levels of systemic re-
constitution with human cells, NSG hu thy/liv mice
develop high levels of human T cells in the peripheral
blood. Remarkably, flow cytometric analysis of blood and
tissues demonstrate the complete absence of human B
and myeloid cells in these mice. Interestingly, in contrast
to mice reconstituted with human peripheral blood mono-
nuclear cells (PBMC) and some other types of human-
ized mice [19,20], these T cell-only mice (or TOM) do
not develop signs of GVHD. In addition, TOM are
readily susceptible to HIV infection after parenteral
exposure and can sustain high levels of HIV replication.
Virus replication can be efficiently suppressed by anti-
retroviral therapy and HIV latency is established in
resting T cells.Results and discussion
SCID-hu (thy/liv) mice have been extensively used as an
in vivo model to study HIV infection of the thymus [7].
Since the original development of the SCID-hu thy/liv
model, new and improved strains of immunodeficient
mice like NOD/SCID and NSG have been developed
[6,8]. We implanted human thymus and liver into NOD/
SCID and NSG mice to determine whether or not these
strains would be an improvement over the SCID-hu
model. We then monitored the peripheral blood (PB) of
these mice over time by polychromatic flow cytometry
for the presence of human cells (hCD45). While the
NOD/SCID implanted mice, like the original SCID-hu
mice, did not have significant levels of human cells in
their PB, the implanted NSG mice had substantial levels
of human reconstitution as determined by presence of
human CD45 in their PB (Figure 1A). Furthermore, hu-
man cells present in the PB of these mice were identified
as T cells by their cell surface expression of human CD3
(Figure 1B). Interestingly, exhaustive analysis for the
presence of other lymphoid or myeloid human cells did
not reveal any significant levels of these cells in the PB
of any animals analyzed. Specifically, we did not detect
human B cells (CD19+), human natural killer cells
(CD56+), or human myeloid cells (CD33+) in the peri-
pheral blood of NSG-implanted mice (Figure 1B). Addi-
tionally, there were no human dendritic cells present in
these mice (Lin-/HLA-DRhi, data not shown). Thy/liv
implanted NSG mice showed sustained production of
human T cells that reached approximately 20% in peri-
pheral blood for up to 30 weeks (the last time point
analyzed). Over this period, no signs of graft-versus-host
disease (GVHD) were observed. Additionally, some ani-
mals were followed for up to 12 months post-implant
(the last time point analyzed). These animals were found
to sustain 20-30% human T cells in the PB even at these
late time points (n = 2, data not shown). From these
results, we concluded that implantation of human thy-
mus and liver into NSG mice results in sustained and
exclusive production of human T cells in vivo.
In SCID-hu mice, human cells are almost exclusively
found in the thymic organoid, with little reconstitution
of PB or tissues [21]. To determine the systemic distri-
bution of the human cells present in NSG mice, mono-
nuclear cells were isolated from the bone marrow,
spleen, lymph nodes, liver, lung, and the thymic orga-
noid. Flow cytometric analyses demonstrated that the
spleen, lymph nodes, liver, lung, and thymic organoid
were robustly reconstituted with human cells (CD45+)
(Figure 2A). Consistent with the lack of hematopoietic
stem cell engraftment in these mice, low levels of human
cells were observed in the bone marrow. To determine if
the tissues were repopulated with human T cells, we
used flow cytometry to assess the presence of hCD3. We
Figure 1 Analysis of the peripheral blood (PB) of thy/liv implanted NSG mice demonstrates long-term reconstitution with human
T cells. A) Flow cytometric analysis of the PB of NOD/SCID-hu (N/S-hu) (black circles) and NSG thy/liv (gray triangles) mice demonstrates
systemic reconstitution of implanted NSG mice with human cells (CD45+; solid line) and human T cells (CD3+; dashed line). Gating strategy: live
cells→human CD45→human CD3. B) Flow cytometric analysis of cells from PB of a representative NSG-hu thy/liv mouse (29 weeks post-implant)
demonstrates these mice are exclusively reconstituted with human T cells with greater than 99% of cells expressing human CD3. There is a lack
of B cells (CD19+), natural killer cells (CD56+), and myeloid cells (CD33+) in the PB of TOM. PB CD3 expressing cells were then analyzed for CD4
and CD8 expression levels. The majority of CD3+ cells in PB expressed CD4 (87%).
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bone marrow, spleen, lymph nodes, liver, and lung were
human T cells (CD3+) (Figure 2B). All tissues and the
peripheral blood were reconstituted with both CD4+ and
CD8+ T cells (Figure 2C). In the thymic organoid, we
also observed a preponderance of human CD3+ cells at
various stages of differentiation [22] (Figure 2B). We also
noted an abundance of double positive (CD4+/CD8+) T
cells, consistent with normal thymopoiesis (Figure 2C).
Additionally, the spleen, small and large intestines of
TOM were analyzed by flow cytometry and immunohis-
tochemistry. In the spleen, T cells were distributed
throughout the entire organ in small groups of cells
similar to those observed in BLT humanized mice [23].In contrast to all other tissues analyzed (including the
spleen) we found no significant levels of human cells
present in the gastrointestinal tract of these animals
(data not shown).
We further investigated the phenotypes of the human T
cells present in PB and tissues. Both CD4+ and CD8+ T
cells from PB and tissues of these mice had a predomi-
nantly naïve phenotype, expressing both human CD45RA
and CD27 (Figure 3). Additionally, we found CD4+ T cells
with central memory (CD45RA-/CD27+) and effector
memory (CD45RA-/CD27-) phenotypes (Figure 3A).
Within the CD8+ T cell population, mainly naïve and
central memory phenotypes were observed, with effector
memory phenotypes being extremely rare in this population
Figure 2 (See legend on next page.)
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Figure 2 Peripheral tissues of implanted thy/liv NSG mice are extensively reconstituted with human T cells. A) Flow cytometric analysis
of cells harvested from the bone marrow (BM), spleen (Spl), lymph nodes (LN), liver (Liv), lung, and the thymic organoid (TO) of implanted thy/liv
NSG mice (n = 15) demonstrated reconstitution with human cells (CD45+). B) Flow cytometric analysis of tissues harvested from an implanted
thy/liv NSG mouse (29 weeks post-implant) demonstrated that all organs were reconstituted exclusively with human T cells or thymocytes. C)
Flow cytometric analysis of tissues and PB harvested from an implanted thy/liv NSG mouse demonstrated that all organs were reconstituted with
both CD4+ and CD8+ T cells.
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CD4+ T cells in these mice have a normal developmental
phenotype.
Once we established the systemic reconstitution of
TOM, we tested whether or not they could support
HIV-1 replication. Eight TOM were infected with a sin-
gle dose of cell-free HIV-1JR-CSF, a CCR5-tropic isolate
administered parenterally. We then monitored the
plasma of TOM for the presence of HIV-1 RNA as pre-
viously described [13,24]. HIV-RNA was detected in the
plasma of TOM one week after exposure and high levelsFigure 3 Naïve/memory phenotype of T cells in the PB and tissues of
memory phenotypes of CD4+ (A) and CD8+ (B) T cells in the PB and tissue
approximately 35 weeks post-implantation on average at time of harvest. (
T cells (TCM) were defined as CD45RAnegCD27+, and effector memory T ce
Mean + SEM.of viremia were maintained over time (Figure 4A). We
also monitored CD4+ T cell depletion in PB, a measure
of HIV pathogenesis. The presence of HIV-RNA in PB
correlated with a subsequent drop in circulating CD4+ T
cells (Figure 4A). Similar decreases in CD4+ T cell levels
were observed in all tissues analyzed consistent with sys-
temic virus spread (Fig. 4B). Phenotypic analysis of the
remaining CD4+ T cells in the infected mice demon-
strated the specific depletion of effector memory T cells
(TEM) cells in PB and tissues (Figure 4C). These results
demonstrate the susceptibility of TOM to HIV infection,TOM. (left) The distribution of central memory, naïve and effector
s of TOM (n = 7) was determined with flow cytometry. Animals were
right) Naïve T cells were defined as CD45RA+CD27+, central memory
lls (TEM) were defined as CD45RAnegCD27neg. Error bars represent the
Figure 4 HIV-1 replication and CD4+ T cell depletion in TOM. A) TOM (n = 8) were parenterally exposed to HIV-1 and the viral load
monitored in PB plasma (black circles). Changes in CD4+ T cell levels in PB were measured over time using flow cytometric analysis (gray
squares). Gating scheme: live cells→ hCD45→ hCD3→ CD4. The limit of detection for viral load is indicated with a dashed line. B) The
percentage of CD4+ T cells present in the tissues of infected (gray bars) and non-infected (black bars) TOM were analyzed using flow cytometric
analysis. Gating scheme: live cells → hCD45→ hCD3→ CD4. C) HIV infection results in a reduction in the levels of effector memory cells within
the CD4+ T cell population of infected mice (n = 5, grey bars) versus uninfected (n = 7, black bars) mice. Infected animals were approximately
48 weeks post-implantation at the time of harvest. For all graphs, error bars represent Mean ± SEM.
Honeycutt et al. Retrovirology 2013, 10:121 Page 6 of 12
http://www.retrovirology.com/content/10/1/121their ability to sustain high levels of virus replication and
the depletion of CD4+ TEM cells from PB and tissues of
infected animals.
Having established the capacity of TOM to support
HIV infection, we proceeded to determine if virus repli-
cation could be suppressed by combination antiretroviral
therapy (ART). For this purpose, HIV infected TOM
were treated daily with a combination of FTC, TDF and
raltegravir. This regimen has been shown by our labora-
tory to effectively suppress viral replication in the
humanized BLT mouse model [13]. To assess the effect-
iveness of ART in infected TOM , levels of HIV-RNA
were monitored in the plasma throughout treatment.
ART administration resulted in a rapid reduction in the
levels of plasma HIV-RNA in all treated animals
(Figure 5B). Five weeks after initiation of treatment the
levels of HIV-RNA in plasma were below the detection
limit of our assay (750 RNA copies/ml). These results
demonstrate the efficacy of ART in controlling HIV rep-
lication in humanized TOM. However, even long-term
ART does not result in virus eradication and treatmentinterruption in patients leads to viral rebound [25]. To
determine if this also occurs in TOM, we executed an
analytical therapy interruption in one HIV infected and
ART suppressed mouse. One week after treatment cessa-
tion, viral RNA was detected in the plasma of this mouse
demonstrating the expected virus rebound (Figure 5C).
In humans, ART results in virus strong virus suppres-
sion, increases in CD4+ T cell levels and other significant
health benefits to patients [26]. Despite this strong virus
suppression seen in ART treated patients, HIV persists
in resting CD4+ T cells that form a long lasting latent
reservoir [27]. To determine if HIV could establish a la-
tent reservoir in TOM, we first confirmed the presence
of resting human T cells in TOM. To assess the presence
of resting human T cells in TOM, we collected cells
from PB, bone marrow, spleen, lymph nodes, liver, lung,
and thymic organoid from HIV+ ART suppressed mice.
Cells from all the tissues obtained from each individual
mouse were pooled together and human CD4+ T cells in
each pool of cells corresponding to one individual
mouse were analyzed for expression of hCD25 and
Figure 5 There is sustained HIV replication in TOM that can be efficiently suppressed by ART. A) Sustained levels of plasma HIV-RNA in
infected TOM (n = 5). B) The plasma viral load of infected TOM (n = 4) pre- and post-initiation of ART treatment demonstrated the ability of ART
to suppress viremia in these mice. ART consisted of daily injections of TDF, FTC and Raltegravir. C) Plasma viral load from an infected TOM
dropped below the limit of detection and remained undetectable for the duration of ART. As seen in humans, viremia rebounded following
treatment interruption. The limit of detection of the assay is indicated with a dashed line. Error bars in both graphs represent the Mean ± SEM.
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significant numbers of resting human CD4+ T cells in
TOM (Figure 6). To determine if resting cells were
latently infected with HIV, pooled cells from all tissues
of each individual ART suppressed mouse were used to
isolate resting CD4+ T cells by negative selection using
magnetic beads [12,13]. After magnetic selection, a
highly purified population of resting CD4+ T cells,
shown by a lack of CD25 and HLA-DR expression was
obtained from each individual mouse (Figure 6). To
quantify the frequency of latently infected resting CD4+
T cells in these mice, we used a protocol validated for
the same purpose for use in humans [28]. Specifically,
the pooled resting cells from each individual mouse were
cultured with efavirenz and raltegravir for two days to
prevent any de-novo infection from unintegrated virus
that may be present. Next, the resting cells were maxi-
mally stimulated in limiting dilutions with PHA, IL-2
and irradiated PBMC from an uninfected donor, follo-
wed by co-culture with allogeneic PHA-activated CD8+-
T-cell-depleted feeder cells. Fifteen days later, cultures
were tested for the presence of HIV (Figure 7A). The
number and density of cultures was then used in a
maximum likelihood method to estimate the number ofinfectious units per million cells (IUPM). Latently infected
cells were obtained from all four animals analyzed
(Figure 7B). IUPM values from mice were compared with
values obtained from outgrowth assays using resting
CD4+ T cells of HIV infected patients treated during the
acute or chronic phase of infection. The levels of latently
infected cells in these mice are within those observed in
the chronic patients receiving suppressive ART [29,30].
To confirm that this indeed is induction from latency, as
an added control, prior to stimulation, supernatant from
resting cell cultures were assayed for P24 and were all
found to be negative (data not shown) suggesting that
virus recovered from outgrowth experiments originated
from latent provirus. These results demonstrate the estab-
lishment of HIV latency in TOM and demonstrate that
in vivo human T cells alone are sufficient for establishing
latency.
Although SCID-hu thy/liv animals have been used
extensively to study thymopoiesis and HIV-1 infection of
the thymus, additional applications of this model has
been limited by the lack of peripheral access to the
human cells [31,32]. Specifically, in this model a lack of
systemic reconstitution with human cells requires invasive
surgery for infection and monitoring of virus replication
Figure 6 Resting human CD4+ T cell isolation from TOM. (Top left) Flow cytometric analysis of cells pooled from the different tissues of a
TOM prior to magnetic negative selection showed the presence of both CD4+ and CD4neg cells. (Bottom left) Prior to negative selection CD4+ T
cells expressed various levels of CD25 and HLA-DR. (Top right) After isolation 99% of the cells obtained were CD4+. (Bottom right) Consistent
with a resting phenotype, isolated cells were CD3+CD4+ and did not express CD25 or HLA-DR. Gating strategy: (Top) live→hCD45+→hCD3+.
(Bottom) live→hCD45+→hCD3+→CD4+.
Figure 7 Latent HIV infection of human resting CD4+ T cells in TOM and human PB. The frequency of latently infected resting CD4+ T cells
was measured in resting CD4+ T cells isolated from ART-suppressed TOM and PB of suppressed patients that initiated treatment during acute or
chronic phases of HIV-1 infection via co-culture of resting cells. A) Diagram depicting the resting cell co-culture assay to detect p24 expression
after maximal stimulation with PHA. B) Comparison of the number of resting HIV infected cells between humanized mice and humans during the
acute or chronic phase of infection. The number of infected resting cells in the individual mice was estimated using a maximum likelihood
method and values reported in infectious units per million resting cells (IUPM).
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and lymph nodes of SCID-hu thy/liv implanted mice were
noted [33]. However, this required implantation of twenty
pieces of human thy/liv tissue under both kidney capsules
of each mouse. Using this more invasive implantation
strategy combined with 20X more tissue, HIV-1 infection
was achieved after IP or intra-implant injection. Using the
original implantation strategy described for SCID-hu mice,
the use of more immunodeficient mouse strains, like the
NSG strain, has overcome the limited systemic reconstitu-
tion previously seen in SCID-hu mice. Interestingly, thy/
liv implantation of NOD/SCID mice did not result in sys-
temic reconstitution with T cells suggesting that the add-
itional immunosuppression due to the lack of a functional
common gamma chain observed in NSG mice resulting in
a complete lack of natural killer cells [34] is likely contrib-
uting to the increased T cell levels in these mice.
TOM were systemically reconstituted with human T
cells. This reconstitution is consistent with the contin-
ued production of human T cells from the implanted
thy/liv organoid as it showed a substantial and robust
population of CD3+/CD4+/CD8+ thymocytes for as long
as the animals were examined (1.2 years). Consistent
with the lack of cryptopatches in NSG mice [35] TOM
showed essentially no significant accumulation of human
T cells in the intestinal tract (data not shown). TOM
show phenotypically normal CD4+ T cell development.
However, we noted somewhat limited CD8+ T cell devel-
opment in TOM, with few effector memory CD8+ cells.
These differences in the formation of effector pheno-
types in the CD4+ and CD8+ T cell populations may be
due to the absence of cytokine signals from professional
APCs as well as CD4+ helper T cells that limit CD8+ T
cell activation/differentiation [22]. The reduction in the
percentage of CD4+ T cells with an effector memory
phenotype pre- and post- HIV infection cannot be
attributed to differences in the source of donor tissues
since tissue from a total of 11 different donors were used
to generate the mice used for these experiments.
One salient feature of TOM is the fact that despite
robust levels of human T cells, they do not develop
GVHD. GVHD has been observed in multiple human-
ized mouse models [19,36]. Some investigators have
reported a significance incidence of GVHD leading to
death of some of the animals at 25-28 weeks post-
humanization [19]. In contrast, we did not notice any of
these effects on TOMs at these or subsequent time
points (up to 78 weeks longest time point analyzed). The
longevity of TOM systemically reconstituted with high
levels of human T cells in the absence of GVHD is an
important feature of this model.
ART offers significant benefits to HIV infected patients.
Our results show that combination ART is able to suppress
viral replication in TOM validating this model for theevaluation of the effect of antivirals on HIV replication
in vivo. As in humans, therapy interruption resulted in
rapid viral rebound. Furthermore, we show that human T
cells alone are sufficient for the establishment of HIV
latency in resting CD4+ T cells. Additionally, latently
infected cells in TOM can be induced ex vivo to produce
virus. The frequency of latently infected resting human
CD4+ T cells in ART suppressed TOM are within the
range seen circulating in PB of ART suppressed patients,
regardless of when therapy was initiated. T cells represent
the major reservoir of latent HIV in humans. Therefore,
TOM may represent a unique tool for studies of HIV
eradication strategies, as they have latently infected resting
CD4+ T cells in the complete absence of any myeloid cells.
Conclusions
In summary, TOM represent a significant advance over
the original SCID-hu thy/liv model because they have
substantial levels of T cells in both PB and tissues. TOM
are systemically and exclusively reconstituted with hu-
man T cells enhancing their utility for the study of T cell
development, repopulation, function and response to
stimuli in vivo. The presence of human T cells in blood
permit direct inoculations with HIV and direct monitor-
ing of virus infection via blood plasma facilitating the
longitudinal analysis of HIV infection and its effects on
CD4+ T cells. ART efficiently inhibits HIV replication in
TOM resulting in strong viral suppression. The ability to
suppress HIV replication by ART in TOM allows the
use of these mice to investigate latently infected resting
human CD4+ cells in vivo. Because these mice do not
develop GVHD and systemic reconstitution with human
T cells is sustained at high levels for over a year, long-
term experiments are greatly facilitated in this model.
Methods
Generation of humanized mice
Humanized TOM were prepared by implanting allogen-
eic thymus and liver tissue into, 6–8 week old NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ (NSG, The Jackson Laboratory)
mice. NOD/SCID hu-thy/liv (N/S-hu) mice were prepa-
red in the same manner by implanting thymus and liver
tissue into NOD.CB17-Prkdcscid/J mice (NOD/SCID,
The Jackson Laboratory). Seven different tissue sets were
used to generate the humanized mice presented in this
manuscript. The thymus and liver implants consisted of a
1-2 mm piece of liver tissue sandwiched between two
pieces of autologous thymus that were placed under the
left kidney capsule (Advanced Bioscience Resources,
Alameda, CA). All mice were maintained in a specific
pathogen-free facility with the Division of Laboratory
Animal Medicine at the University of North Carolina at
Chapel Hill (UNC-CH) according to protocols approved
by the Institutional Animal Care and Use Committee.
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cytometric analysis for human CD45+ cells in peripheral
blood, as previously described [37,38]. Peripheral blood
samples were obtained via submandibular venipuncture
and were collected in tubes containing EDTA. Whole per-
ipheral blood was stained with antibodies, red blood cells
were lysed, and the remaining cells were washed and fixed
using a 1% paraformaldehyde solution. A total of 10,000-
30,000 events were collected per animal at each time point
as indicated below.
Tissue harvesting and flow cytometric analyses of
humanized mice
Mononuclear cells (MNCs) were isolated from the bone
marrow, spleen, lymph nodes, lung, liver, and thymic
organoid as previously described [38]. Tissues were
minced and/or digested and filtered through a 70 μm
strainer. The liver and lung were processed as previously
described [39]. For all latency determinations, mono-
nuclear cells, with the exception of the lymph nodes,
were isolated using a Percoll gradient. Red blood cells
were lysed as needed (namely for the spleen, bone mar-
row and liver tissues). MNCs were washed, counted via
trypan blue exclusion, and flow cytometric analyses were
performed for the indicated markers [13,24,37-39]. Live
cells were distinguished by their forward and side scatter
profiles as previously described [40]. Flow cytometry
data was collected on either a BD FACSCanto or a BD
LSRFortessa flow cytometer, and analyzed using BD
FACSDiva software (v.5.0.2 or v.6.1.3).
HIV-1 infections
Stocks of HIV-1JR-CSF were prepared and titered as pre-
viously described [41]. Briefly, virus supernatants were
prepared via transient transfection of 293 T cells, and were
tittered using TZM-bl cells essentially as we have previ-
ously described [42]. Parenteral exposures were performed
using HIV-1JR-CSF (90,000 TCIU) administered either intra-
venously or intraperitoneally. A total of two intraperitoneal
and six intravenous exposures were performed, yielding 2/
2 and 6/6 systemically infected animals, respectively.
Analysis of HIV-1 infection
Peripheral blood was collected via retro-orbital bleed
using EDTA coated capillary tubes (approximately 100
ul total). Infection of TOM with HIV-1 was determined
with a one-step reverse transcriptase real-time PCR
assay (ABI custom TaqMan Assays-by-design) according
to the manufacturer’s instructions (with primers 5′-CA
TGTTTTCAGCATTATCAGAAGGA-3′ and 5′-TGCT
TGATGTCCCCCCACT-3′; assay sensitivity of 400 RNA
copies per mL). Additionally, the percent of human CD4+
T cells in the peripheral blood of TOM pre- and post-
exposure to HIV-1 were monitored by flow cytometry(using 40-60 ul of blood). Changes in the percent of
CD4+ T cells present in the tissues of infected and
uninfected animals were compared by two-way ANOVA,
and were not significantly different. Statistical analysis was
performed in Prism version 5 (GraphPad Software, Inc.,
San Diego, CA).Antiretroviral treatment of TOM
For HIV treatment we used a previously described triple
combination of drugs that we have shown to be effective
at suppressing viral load in humanized mice. Specifically,
infected TOM were administered daily intraperitoneal
injections of emtricitabine (FTC; 140-200 mg/kg), teno-
fovir disoproxil fumarate (TDF; 146-208 mg/kg) and
raltegravir (RAL; 56-80 mg/kg) for six to nine weeks, as
previously described [13]. HIV-1 infection was monito-
red throughout ART as described above.Resting cell isolation and latency determinations of TOM
and patient samples
All MNCs from individual mice were pooled. Resting
human CD4+ T cells were isolated from pooled tissues
or from leukopheresis product of patient samples using
negative magnetic selection (STEMCELL Technologies,
Vancouver) as previously described [12,13,43]. Briefly,
MNCs obtained from mouse tissues were incubated with
a cocktail of antibodies composed of mouse anti CD45
and TER119, and anti-human CD8, CD14, CD16, CD19,
CD56, CD41, CD25, CD31, CD105, HLA-DR, and gly-
cophorin A. For the separation of cells from human
samples, the mouse antibodies were not included in the
isolation cocktail. Antibody-bound cells were removed
using a column based-magnetic purification system and
the purified resting cells were collected as flow through.
This approach resulted in a >99% pure resting CD4+ T
cell population. Resting CD4+ T cells were then cultured
with 15 nM efavirenz and 1 μM raltegravir for 2 days
prior to performing viral outgrowth assays to prevent
any de-novo infection from unintegrated virus [13]. Viral
outgrowth was achieved by maximally stimulating rest-
ing cells in limiting dilution cultures containing 60 U/ml
IL-2, 1ug/ml phytohemagglutinin (PHA) and irradiated
allogeneic PBMC from an uninfected donor.al. [12,13].
The culture media was replaced every 3-4 days with
fresh media containing 5 U/ml IL-2. CD8 depleted
PHA-stimulated PBMC from an uninfected donor were
added twice during the experiment to facilitate virus
spread/amplification in cultures. Cultures were scored
positive if p24 was detectable at day 15 and confirmed
on day 19. The number of infected resting cells was
estimated by a maximum likelihood method and was
expressed as the infectious units per million resting CD4+
T cells (IUPM) [12].
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